

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3 Attorney Docket Number 08841.105020 PHA 1070 US



Complete if Known

Application Number	10/632,997
Filing Date	August 1, 2003
First Named Inventor	Peiyuan Wang <i>et al.</i>
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	08841.105020 PHA 1070 US

3399974_1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear	T ⁶
		Number	Kind Code (if known)				
C#	AA	5,026,687		Yarchoan <i>et al.</i>	06-25-1991		
C#	AB	5,491,135		Blough	02-13-1996		
C#	AC	5,496,546		Wang <i>et al.</i>	03-05-1996		
C#	AD	5,633,388		Diana <i>et al.</i>	05-27-1997		
C#	AE	5,725,859		Omer	03-10-1998		
C#	AF	5,830,905		Diana <i>et al.</i>	11-03-1998		
C#	AG	5,837,257		Tsai <i>et al.</i>	11-17-1998		
C#	AH	5,846,964		Ozeki	12-08-1998		
C#	AI	5,849,800		Smith	12-15-1998		
C#	AJ	5,858,389		Elsherbini	01-12-1999		
C#	AK	5,891,874		Colacino <i>et al.</i>	04-06-1999		
C#	AL	5,922,757		Chojkier	07-13-1999		
C#	AM	6,030,960		Morris-Natschke <i>et al.</i>	02-29-2000		
C#	AN	6,034,134		Gold <i>et al.</i>	03-07-2000		
C#	AO	6,056,961		Lavie <i>et al.</i>	05-02-2000		
C#	AP	6,573,248	B2	Ramasamy <i>et al.</i>	06-03-2003		
C#	AQ	2002/0055483	A1	Watanabe <i>et al.</i>	05-09-2002		
C#	AR	2002/0147160	A1	Bhat <i>et al.</i>	10-10-2002		
C#	AS	2003/0008841	A1	Devos <i>et al.</i>	01-09-2003		
C#	AT	2003/0028013	A1	Wang <i>et al.</i>	02-06-2003		
C#	AU	2003/0050229	A1	Sommadossi <i>et al.</i>	03-13-2003		
C#	AV	2003/0060400	A1	LaColla <i>et al.</i>	03-27-2003		
C#	AW	2003/0083307	A1	Devos <i>et al.</i>	05-01-2003		
C#	AX	2003/0087873	A1	Stuyver <i>et al.</i>	05-08-2003		

Examiner Signature	<i>Caren Daugh</i>	Date Considered	3/29/07
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/632,997
Filing Date	August 1, 2003
First Named Inventor	Peiyuan Wang <i>et al.</i>
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	08841.105020 PHA 1070 US

3399974 1

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office ³	Number	Kind Code ² (if known)				
Cit	BA	FR	2,662,165	A1 ✓	Univ Pierre et Marie Curie	11-22-1991		
Cit	BB	WO	98/16184	A2 ✓	ICN Pharmaceuticals	04-23-1998		
Cit	BC	WO	99/43691	A1 ✓	Emory University	09-02-1999		
Cit	BD	WO	01/32153	A2 ✓	BioChem Pharma Inc.	05-10-2001		
Cit	BE	WO	01/60315	A2 ✓	BioChem Pharma Inc.	08-23-2001		
Cit	BF	WO	01/68663	A1 ✓	ICN Pharmaceuticals Inc.	09-20-2001		
Cit	BG	WO	01/79246	A2 ✓	Pharmasset, Ltd.	10-25-2001		
Cit	BH	WO	01/90121	A2 ✓	Novirio (Idenix Pharmaceuticals)	11-29-2001		
Cit	BI	WO	01/92282	A3 ✓	Novirio Pharm.; Univ...Cagliari	06-12-2001		
Cit	BJ	WO	02/003997	A1 ✓	ICN Pharmaceuticals Inc.	01-17-2002		
Cit	BK	WO	02/018404	A2 ✓	F. Hoffmann-La Roche AG	03-07-2002		
Cit	BL	WO	02/032920	A2 ✓	Pharmasset Ltd.	04-25-2002		
Cit	BM	WO	02/048165	A2 ✓	Pharmasset, Ltd.	06-20-2002		
Cit	BN	WO	02/057287	A2 ✓	Merck; Isis Pharmaceuticals	07-25-2002		
Cit	BO	WO	02/057425	A2 ✓	Merck; Isis Pharmaceuticals	07-25-2002		
Cit	BP	WO	02/070533	A3	Pharmasset, Ltd.	09-12-2002		
Cit	BQ	WO	02/094289	A1	F. Hoffmann-La Roche AG	11-28-2002		
Cit	BR	WO	02/100415	A2	F. Hoffmann-La Roche AG	12-19-2002		
Cit	BS	WO	03/026589	A2	Idenix; C.N.R.S.; U. Montpelier	04-03-2003		
Cit	BT	WO	03/026675	A1	Novirio (Idenix Pharmaceuticals)	04-03-2003		
Cit	BU	WO	03/051899	A1	Ribapharm Inc.	06-26-2003		
Cit	BV	WO	03/061385	A1	Ribapharm Inc.	07-31-2003		
Cit	BW	WO	03/061576	A2	Ribapharm Inc.	07-31-2003		
Cit	BX	WO	03/062255	A2	Ribapharm Inc.	07-31-2003		
Cit	BY	WO	03/062256	A1	Ribapharm Inc.	07-31-2003		
Cit	BZ	WO	03/062257	A1	Ribapharm Inc.	07-31-2003		


Examiner Signature	<i>Carles Daugh</i>	Date Considered	3/29/07
--------------------	---------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	3	Attorney Docket Number	08841.105020 PHA 1070 US
-------	---	----	---	------------------------	--------------------------

3399974_1

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
CH	CA	WO	03/063771	A2	Pharmasset Ltd.	08-07-2003		
CH	CB	WO	03/068162	A2	Pharmasset Ltd.	08-21-2003		
CH	CC	WO	03/072757	A2	Biota Inc.	09-04-2003		
CH	CD	WO	03/093290	A2	Genelabs Technologies	11-13-2003		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
CH	CE	ANDERSON, G. L., et al., "Pyridopyrimidines. 7. Ribonucleosides structurally related to the antitumor antibiotic sangivamycin," <i>J. Org. Chem.</i> , 42(6):997-1000 (1977).	
CH	CF	CARROLL, Steven S. et al. "Inhibition of Hepatitis C Virus RNA Replication by 2'-Modified Nucleoside Analogs" <i>The Journal of Biological Chemistry</i> , 278(14):11979-11984 (2003).	
CH	CG	DYMOCK, B.W., et al., "Novel approaches to the treatment of hepatitis C virus infection," <i>Antiviral Chemistry & Chemotherapy</i> , 11(2):79-96 (2000).	
CH	CH	HARRY-O'KURU, Rogers E. et al. "2'-C-Alkyribonucleosides: Design, Synthesis, and Conformation" <i>Nucleosides & Nucleotides</i> , 16(7-9):1457-1460 (1997).	
CH	CI	PFLEIDERER, W., et al., "Allgemeine Synthese von Pteridin-N-8-glycosiden," <i>Chem. Ber.</i> , 106, 317-331 (1973).	
CH	CJ	RIZKALLA, B.H., et al., "Pyrido[2,3-d]pyrimidines. III. Synthesis of some 8-(β-D-ribofuranosyl)pyrido[2,3-d]pyrimidines structurally related to the antibiotic sangivamycin," <i>J. Org. Chem.</i> , 37(25):3980-3985 (1972).	

3399974_1

Examiner Signature		Date Considered	3/29/07
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
				<i>Application Number</i>	10/632,997
				<i>Filing Date</i>	August 1, 2003
				<i>First Named Inventor</i>	Peiyuan WANG
				<i>Art Unit</i>	1617
				<i>Examiner Name</i>	Carlic K. Huynh
				<i>Attorney Docket Number</i>	09797.0002-00

(Use as many sheets as necessary)

Sheet 1 of 1

JAN 18 2007 U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
CH		JP 5-140179 A	06/08/1993	Shouy KK Yamasa		No

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
CH		SASAKI et al., "Reactions of the Derivatives of 5-Bromopyrimidine Nucleosides with Sodium Azide", Journal of Organic Chemistry, Vol. 41, No. 7, pp. 1100-1104, (1976)	
CH		MILES et al., "Circular Dichroism of Nucleoside Derivatives. X. Influence of Solvents and Substituents upon the Cotton Effects of Guanosine Derivatives", Journal of the American Chemical Society, Vol. 93, No. 7, pp. 1600-1608, (April 7, 1971)	
CH		Notification of Transmittal of the International Search report	

Examiner Signature	<i>Carlic K. Huynh</i>	Date Considered	3/29/07
--------------------	------------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.